Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Parkinson’s disease is a chronic and progressive condition affecting the brain and nervous system. It impacts millions of ...
The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...
A 65-year-old retired nurse said she had got her life back thanks to a new drug used to treat Parkinson's disease which ...
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.
Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
HealthDay on MSN12d
Costs for MS, Parkinson's and Alzheimer's Meds Keep RisingA person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 202 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback